Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study

Finding the best options for combined antihypertensive therapy is one of the main tasks to be solved for achieving target blood pressure (BP) and, accordingly, reduction of the risk of complications in patients with arterial hypertension (AH).

Purpose of this study was to evaluate the effectiveness of the perindopril arginine/amlodipine fixed combination in patients with 1-2 degree hypertension not achieving BP control on previous therapy with sartan-containing free combinations.

Materials and methods. In the multicenter open uncontrolled observational program AVANGARD 203 doctors in 53 cities of the Russian Federation included 658 patients who had not achieved target BP on therapy with two drugs, one of which was sartan (sartan with diuretic, calcium antagonist, β-blocker, or moxonidine in 49%, 33%, 17%, and 1% of cases, respectively). This therapy was replaced with a fixed combination of perindopril arginine/amlodipine. Duration of observation was 3 months.

Results. On therapy with perindopril arginine/amlodipine, BP decreased 159.9±8.5/92.1±7.4 to 125.8±7.1/77.4±5.5 mm Hg. Target BP <140/90 mm Hg was achieved in 93.5% of patients (office measurement); target BP <135/85 mm Hg - in 83.5% of patients (home measurement). Mean 24-hour BP variability decreased from 4.4±2.9/3.0±2.0 to 3.0±2.2/2.2±1.7 mm Hg (p<0.01). Number of patients complaining of headache decreased by 2.9 times, dizziness - by 2.8 times, fatigue - by 2.3 times, irritability - by 3.0 times, sleep disturbances - by 2.3 times, dyspnea - by 3.8 times, palpitations - by 2.7 times, angina pectoris attacks - by 4.6 times. Dose of perindopril arginine/amlodipine was 10/5 mg in 36.6%, and 10/10 mg in 28.3% of cases, respectively. Number ofparticipants who dropped out ofthe study prematurely was 11 (1.6%) (1 because of adverse event). Adverse events were observed in 4 more patients (2 [0.14%] - edema of lower extremities, and 2 [0.14%] -cough), but they did not require the withdrawal of therapy.

Conclusion. In case of ineffective combination therapy containing sartans, transfer of patients to a fixed combination of perindopril and amlodipine should be considered.

1. Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT et al. Systematic Review for the 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/AS H/ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e116-35. DOI: 10.1161/HYP.0000000000000067

2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2224-60. DOI: 10.1016/S0140-6736(12)61766-8

3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-82. DOI: 10.1001/jama.2016.19043

4. Boytsov S.A., Balanova Yu.A., Shal'nova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M. et al. Arterial hypertension among persons aged 25-64: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. DOI: 10.15829/1728-8800-2014-4-4-14

5. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms. Circulation Research. 2015;116(6):991-1006. DOI: 10.1161/CIRCRESAHA.116.305697

6. Skibitsky VV., Fendrikova A.V., Opolskaya S.V. Antihypertensive and vasoprotective effectiveness of the chronopharmacotherapy in patients with arterial hypertension after acute cerebrovascular accident. Kardiologiia. 2019;59(1S):25-33. DOI: 10.18087/cardio.2537

7. Hermida RC, Ayala DE, Fernandez JR, Mojon A, Smolensky MH. Hypertension: New perspective on its definition and clinical management by bedtime therapy substantially reduces cardiovascular disease risk. European Journal of Clinical Investigation. 2018;48(5):e12909. DOI: 10.1111/eci.12909

8. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database of Systematic Reviews. 2018;6:CD012675. DOI: 10.1002/14651858.CD012675.pub2

9. Etebari F, Pezeshki MZ, Fakour S. Factors related to the nonadherence of medication and nonpharmacological recommendations in high blood pressure patients. Journal of Cardiovascular and Thoracic Research. 2019;11(1):28-34. DOI: 10.15171/jcvtr.2019.05

10. Hedna K, Hakkarainen KM, Gyllensten H, Jonsson AK, Andersson Sundell K, Petzold M et al. Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications? PLOS ONE. 2015;10(9):e0137451. DOI: 10.1371/journal.pone.0137451

11. Glezer M.G. The Use of Fixed Perindopril A/Amlodipine Combination Provides High Compliance to Therapy, Effective and Safe Arterial Pressure Lowering in Patients With Previous Inefferctive Therapy. The POTENTIAL Program. Kardiologiia. 2015;55(12):17-24.

12. Glezer M.G., Deev A.D. How to Increase the Effectiveness of Antihypertensive Therapy in Clinical Practice: Results of the Russian Observational Program FORSAZH. Kardiologiia. 2016;56(1):18-24. DOI: 10.18565/cardio.2016.1.13-24

13. Kotovskaya Yu.V., Villevalde S.V., Tigai Zh.G., Kobalava Zh.D. Hypertensive patients' adherence, motivation, and awareness during fixed-dose perindopril A and amlodipine combination treatment (Results of the CONSTANTA trial). Terapevticheskii Arkhiv. 2015;87(2):64-9. DOI: 10.17116/terarkh201587264-69

14. Druzhilov M.A., Kuznetsova T.Yu. Internal obesity as a risk factor for arterial hypertension. Russian Journal of Cardiology. 2019;4:7-12. DOI: 10.15829/1560-4071-2019-4-7-12

15. Dobrynin N.V., Yakushin S.S. Effective blood pressure reduction: results of the regional program “DOVERIE." Russian Journal of Cardiology. 2018;12:57-63. DOI: 10.15829/1560-4071-2018-12-57-63

16. Ivanovic B, Tadic M. Hypercholesterolemia and Hypertension: Two Sides of the Same Coin. American Journal of Cardiovascular Drugs. 2015;15(6):403-14. DOI: 10.1007/s40256-015-0128-1

17. Chopra I, Kamal KM. Factors Associated With Therapeutic Goal Attainment in Patients With Concomitant Hypertension and Dyslipidemia. Hospital Practice. 2014;42(2):77-88. DOI: 10.3810/hp.2014.04.1106

18. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003;361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0

19. Di Martino M, Esposti LD, Filigheddu F, Veronesi C, Salerno G, Saragoni S et al. Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice. Journal of Human Hypertension. 2007;21(1):53-9. DOI: 10.1038/sj.jhh.1002102

20. Tanabe A, Asayama K, Hanazawa T, Watabe D, Nomura K, Okamura T et al. Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control: HOMED-BP study. Hypertension Research. 2017;40(5):504-10. DOI: 10.1038/hr.2016.176

21. Astashkin E.I., Glezer M.G. Mechanisms of combined action of ace inhibitors and calcium antagonists in arterial hypertension. Cardiovascular Therapy and Prevention. 2013;12(3):72-7. DOI: 10.15829/1728-8800-2013-3-72-77

22. Ogilvie RI, Anand S, Roy P, De Souza S. Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk Factors: An Open-Label, Observational, Multicentre, General Practice-Based Study. Clinical Drug Investigation. 2008;28(11):673-86. DOI: 10.2165/00044011-200828110-00001

23. Ionescu D-D. Antihypertensive Efficacy of Perindopril 5-10 mg/day in Primary Health Care: An Open-Label, Prospective, Observational Study. Clinical Drug Investigation. 2009;29(12):767-76. DOI: 10.2165/11319700-000000000-00000

24. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions. 2009;9(3):135-42. DOI: 10.2165/00129784-200909030-00001

25. Degli Esposti L, Perrone V, Veronesi C, Gambera M, Nati G, Perone F et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlo-dipine-perindopril in real settings (AMPERES) study. Current Medical Research and Opinion. 2018;34(9):1571-7. DOI: 10.1080/03007995.2018.1433648

26. Mancia G, Asmar R, Amodeo C, Mourad J-J, Taddei S, Gamba MAA et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. Journal of Hypertension. 2015;33(2):401-11. DOI: 10.1097/HJH.0000000000000409

27. Poulter NR, Dolan E, Gupta AK, O'Brien E, Whitehouse A, Sever PS. Efficacy and Safety of Incremental Dosing of a New SinglePill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs. 2019;19(3):313-23. DOI: 10.1007/s40256-018-00314-4

28. Satoh M, Maeda T, Hoshide S, Ohkubo T. Is antihypertensive treatment based on home blood pressure recommended rather than that based on office blood pressure in adults with essential hypertension? (meta-analysis). Hypertension Research. 2019;42(6):807-16. DOI: 10.1038/s41440-019-0221-y

29. Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. Journal of the American Society of Hypertension. 2016;10(3):224-234.e17. DOI: 10.1016/j.jash.2015.12.013

30. Breaux-Shropshire T, Judd E, Vucovich L, Shropshire T, Singh S. Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. Integrated Blood Pressure Control. 2015;8:43-9. DOI: 10.2147/IBPC.S49205

31. Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G. Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes. Diabetes Care. 2013;36(Supplement_2):S312-24. DOI: 10.2337/dcS13-2043

32. Dyakov I.N., Glezer M.G. Evaluation of the pharmacoeco-nomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program. Terapevticheskii arkhiv. 2016;88(11):83-90. DOI: 10.17116/terarkh2016881183-90